Trial Profile
A study of ADXS-DUAL and Nivolumab for the treatment of metastatic cervical cancer in women
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2023
Price :
$35
*
At a glance
- Drugs ADXS Dual (Primary) ; Nivolumab (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
- 11 Sep 2017 According to an Advaxis media release, this trial will be initiated in 1H 2018.
- 13 Jun 2017 According to an Advaxis media release, this study has been previewed at annual Investor & Analyst Day.